Evonile Pharma share price, P/E, ROE & financials

On 6 Nov 2026, Evonile Pharma was priced at ₹1,758.40, or 44.4× trailing earnings, and the shares are 32% below their 52-week high. It earns ROCE of 16% and ROE of 12%, and sales and net profit fell 1.4% and 3.4% a year over 3 years. It is a small-cap company with a market cap of ₹4,342 Cr; the shares rose 162% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹1,701.00
Day high: ₹1,785.00
Day low: ₹1,695.00
Prev. close: ₹1,716.50
Volume: 52.7K

Health check

1 good · 1 fair · 2 to check

ReturnsStrong
+161.6% over the past year.
Price tagNo peers
P/E 44.4, with no peers to compare.
GrowthShrinking
Sales −1.4%, profit −3.4% a year over 3 years.
ProfitabilityAverage
ROCE 15.7%.
Balance sheetn/a
Balance sheet figures aren’t reported.
Red flags1 to check
32% below its 52-week high.

Computed from reported figures. Educational, not a recommendation.

Other

Screen the industry

Small cap

₹4,342 Cr

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹354 Cr · profit ₹93 Cr

Market cap: ₹4,342 Cr; Small cap
P/E: 44.4
Price to book: 5.31; Book value ₹331.23
Dividend yield: n/a
ROE: 11.6%; Return on equity
ROCE: 15.7%; Return on capital employed
Debt to equity: n/a
EPS (TTM): ₹39.61; Face value ₹5
OPM (TTM): n/a
Sales growth: +18.6%; Latest quarter vs a year ago
Profit growth: +16.6%; Latest quarter vs a year ago
Price to sales: 12.25

Strengths

Quarterly sales up 18.6% on a year ago.
Positive operating cash flow in each of the last 4 years.

Risks to check

32% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Evonile Pharma

No company description is available.

ISIN: INE234A01025

Price range

52 weeks

₹672.25₹2,588.80

Today

₹1,695.00₹1,785.00

Avg volume (3M): 1 L
1-year return: plus 161.6%
From 52-week high: minus 32.1%

Peers

We couldn’t find listed peers for this company.

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
83.9	87.6	–	85.9	90.6	104
–	–	–	–	+8.0%	+18.6%
60.2	60.3	–	63.6	70	68.9
23.7	27.2	–	22.3	20.6	34.9
28.3%	31.1%	–	26.0%	22.7%	33.7%
10.6	10.6	–	8.8	10	8.7
0.1	0.1	–	1	0.1	0.1
0.5	0.5	–	0.5	0.4	0.4
0.2	0	–	0	0.1	−0
33.9	37.2	–	29.7	30.1	43.2
13.5%	25.8%	–	45.7%	16.2%	25.4%
29.3	27.6	–	16.1	25.3	32.2
–	–	–	–	minus 13.8%	+16.6%
–	11.19	9.81	6.52	10.23	13.05

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: −1.4%
Profit CAGR 3Y: −3.4%
ROE: 11.6%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
369	334	356	354
–	minus 9.5%	+6.7%	minus 0.5%
294	266	260	258
75.3	67.9	96.4	96.4
20.4%	20.3%	27.0%	27.2%
54.2	55.5	41.6	36.5
1.8	1.5	0.8	1.3
6.1	2.6	2.2	2
−6.3	3.6	−4.5	0
115	123	130	130
10.4%	30.6%	22.6%	28.1%
103	85.2	101	93.2
–	minus 17.6%	+18.4%	minus 7.7%
–	34.50	40.87	37.74

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
12.3	12.3	12.3	12.3
763	732	773	805
21.5	7	5.1	3.2
186	173	158	157
983	925	948	978
19.3	6.9	4.5	2.9
0.6	0.3	0.2	0.1
554	585	637	658
409	333	306	318
983	925	948	978

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
44.8	113	74.6	46.7
−153	33.1	−3.3	17.6
−30.5	−121	−64.2	−63.9
−139	25.5	7.1	0.4
−0.3	–	–	−0.3
44.5	113	74.6	46.4
−24.7	−117	−61.7	−61.7

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company.

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you